# Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

> **NCT02892149** · PHASE3 · COMPLETED · sponsor: **Akebia Therapeutics** · enrollment: 3554 (actual)

## Conditions studied

- Anemia
- Dialysis-Dependent Chronic Kidney Disease

## Interventions

- **DRUG:** Vadadustat
- **DRUG:** Darbepoetin alfa

## Key facts

- **NCT ID:** NCT02892149
- **Lead sponsor:** Akebia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2020-01-16
- **Final completion:** 2020-03-30
- **Target enrollment:** 3554 (ACTUAL)
- **Last updated:** 2022-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02892149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02892149, "Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02892149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*